ACTR-94. TOXICITY OF SINGLE AGENT CARMUSTINE VERSUS CARMUSTINE PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT OR PROGRESSIVE HIGH GRADE GLIOMAS

BACKGROUND: An increased incidence in hematologic toxicity has been reported with the addition of bevacizumab to lomustine for patients with recurrent or progressive high grade gliomas (HGG). Data regarding incidence of toxicity with combination bevacizumab and carmustine (BCNU) is limited. The purp...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Yerram, Prakirthi, Reiss, Samantha, Modelevsky, Lisa, Gavrilovic, Igor, Kaley, Thomas
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2017
Pynciau:
Abstracts
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692428/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.078
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg